PYPD

Polypid Ltd.

• TipRanks·10/12 16:15

  PolyPid management to meet virtually with Craig-Hallum

• TipRanks·10/09 12:30

  What PolyPid’s Bold Moves in Europe Could Mean for D-PLEX₁₀₀’s Global Potential (NASDAQ: PYPD)

• TipRanks·10/01 13:48

  PolyPid’s D-PLEX₁₀₀ Application Validated by EMA, Advancing Dual EU–U.S. Reviews

• TipRanks·10/01 13:29

  PolyPid Reclaims European Rights to D-PLEX₁₀₀ After Ending Advanz Pharma Deal

• Benzinga·10/01 13:11

  PolyPid Agrees With ADVANZ PHARMA To Terminate Their 2022 Exclusive License, Distribution And Supply Agreement For D-PLEX₁₀₀ In Europe

• TipRanks·10/01 13:00

  PolyPid regains European commercialization rights for D-PLEX

• TipRanks·08/14 02:30

  Analysts Are Bullish on These Healthcare Stocks: PolyPid (PYPD), Equillium (EQ)

• TipRanks·08/13 00:12

  PolyPid Earnings Call: Priority Review, Big Azurity Deal

• TipRanks·08/12 21:17

  PolyPid Posts Wider H1 2026 Loss as Assets and Equity Decline

• NASDAQ·08/12 18:45

  PolyPid Advances D-PLEX100; FDA Grants Priority Review

• TipRanks·08/12 16:50

  Analysts Offer Insights on Healthcare Companies: BioNano Genomics (BNGO), Liquidia Technologies (LQDA) and PolyPid (PYPD)

• TipRanks·08/12 11:57

  PolyPid Wins FDA Priority Review for D-PLEX₁₀₀ and Locks In $30 Million Azurity Milestones

• Benzinga·08/12 11:30

  PolyPid Q2 EPS $(0.35) Beats $(0.38) Estimate

• Seeking Alpha·07/29 18:20

  PolyPid rises as lead product granted FDA priority review

• TipRanks·07/29 15:30

  PolyPid NDA acceptance ‘meets or exceeds’ expectations, says Roth Capital